Background-Heart failure (HF) is a prevalent and deadly disease, and preventive strategies focused on at-risk individuals are needed. Current HF prediction models have not examined HF subtypes. We sought to develop and validate risk prediction models for HF with preserved and reduced ejection fraction (HFpEF, HFrEF). Methods and Results-Of 28,820 participants from 4 community-based cohorts, 982 developed incident HFpEF and 909
Predicting Heart Failure Subtypes
H eart failure (HF) is a major growing public health burden worldwide. One in 5 men and women will develop HF in their lifetime. 1 In the United States alone, it is estimated that >8 million people will be living with HF by the year 2030, with projected direct medical costs of HF doubling in the next 20 years to $53 billion, and similar trends are projected worldwide. 2, 3 The need for strategies to prevent HF has sharpened the focus on identifying and treating high-risk asymptomatic individuals, classified as American Heart Association and American College of Cardiology stage A or B HF. 2, 4 Several recent initiatives have advocated for primary prevention and aggressive treatment of at-risk individuals, 5, 6 yet this group of individuals remains ill defined with respect to their exact risk for HF. This emphasis on disease prevention highlights the potential importance of risk prediction of future HF.
See Clinical Perspective
Previous population-based studies on HF risk prediction models have often lacked external validation, and more importantly, none have taken into account HF subtypes. 7 Current recommended therapies for HF with preserved ejection fraction (HFpEF) differ considerably from therapies instituted for HF with reduced ejection fraction (HFrEF). 4, 8 It is also thought that HFpEF and HFrEF are 2 distinct HF phenotypes with different etiologic factors. 9 Accordingly, we hypothesized that risk predictors of HFpEF would be distinct from those preceding HFrEF. Previous studies have revealed some differences in risk factor profiles among incident HFpEF versus HFrEF. [10] [11] [12] Findings were restricted to single cohorts, however, and risk prediction was limited by the challenge of handling multiple competing risks when examining HF subtypes.
To examine HF subtype-specific risk profiles, we assembled an international consortium of 4 longitudinal community-based cohorts, each of which classified incident HF cases as HFpEF or HFrEF. We developed and validated separate risk prediction models for HFpEF and HFrEF. Our findings may help delineate and phenotype individuals at risk for specific HF subtypes and may be useful in targeting future preventive strategies.
Methods

Study Sample
Four prospective, observational, community-based cohorts with adjudicated incident HF outcomes were included: the Framingham Heart Study (FHS) original and offspring cohorts, the Cardiovascular Health Study (CHS), the Prevention of Renal and Vascular Endstage Disease (PREVEND), and the Multi-Ethnic Study of Atherosclerosis (MESA). [13] [14] [15] [16] [17] Participants from the following baseline examinations were included: FHS original cohort examination 16 (1979-1982) or 24 (1995-1998) , FHS offspring cohort examination 2 (1979-1983) or 6 (1995-1998) , CHS examination 1 (1989-1990; 1992-1993 for supplemental African-American cohort), PREVEND examination 1 (1997-1998), or MESA examination 1 (2000) (2001) (2002) . Individuals with prevalent HF (n=472), age <30 years at baseline examination (n=379), or those with missing covariates (n=2177) were excluded, leaving 28 820 individuals for analysis. Participants were monitored for the first HF event occurring ≤15 years after the baseline examination. Written informed consent was obtained, and institutional review board approval was obtained at all participating institutions. For cohort-specific details, see Methods section in the Data Supplement.
Clinical Assessment
All participants had detailed medical history, physical examination, fasting laboratory assessment, and electrocardiography at the baseline examination. All potential risk factors were evaluated and harmonized across cohorts whenever possible. Blood pressure was taken as the average of 2 seated measurements. Body mass index was calculated as weight divided by height 2 and expressed as kg/m 2 . Diabetes mellitus was defined as a fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL, or the use of hypoglycemic medications. Modest alcohol use was defined as ≥1 drink per day in both men and women. Electrocardiographic left ventricular (LV) hypertrophy was defined based on accepted voltage and ST-segment criteria (Methods section in the Data Supplement).
Definition of Incident HF Subtypes
Individuals were followed up prospectively for the occurrence of incident HF or death. Outcomes were adjudicated using established protocols by study investigators within each cohort after review of all available outpatient and hospital records. HF was defined using a combination of signs and symptoms (Methods section in the Data Supplement). Records were reviewed for LV function assessment at or around the time of the first HF presentation. Each incident HF event was categorized as HFpEF (left ventricular ejection fraction [LVEF] >45%), HFrEF (LVEF ≤45%), or unclassified (no LV function assessment available). LV function was ascertained by echocardiography in >85% of cases in all 4 cohorts.
Statistical Analysis
Baseline clinical characteristics were summarized by cohort. Individual-level data were pooled for FHS, CHS, and PREVEND after harmonizing definitions of clinical variables. Internal derivation and validation sets were created using a random 2:1 split in the pooled sample.
Cumulative incidence rates of HFpEF and HFrEF were estimated using a Kaplan-Meier-like method accounting for competing risks (death, other HF subtype, and unclassified HF). 18 Fine-Gray proportional subdistribution hazards models were fitted for overall HF and separately for HFpEF and HFrEF. 19 Given that incident all-cause mortality was not negligible among cohorts studied, death was treated as a competing risk event to avoid informative censoring. In addition to accounting for competing risk of death, analyses also accounted for competing risks of other HF subtype and unclassified HF in PSHREG (SAS). 20 First, age-and sex-adjusted models were fitted for each clinical covariate. Given sex differences in HDL cholesterol, sex-specific centered HDL was used in models. Covariates associated with HF at a P≤0.10 were entered into a stepwise selection model, forcing in age and sex, and using a Bonferroni-corrected P-value threshold for retention (P=0.05/number of covariates considered for entry). A strata statement was included to specify study cohorts within the pooled analysis.
We assessed validation using the final multivariable HF subtypespecific models and cohort-specific null hazards. To assess model discrimination, the c-statistic was calculated using predicted event probabilities and times to events. 21 We created model-based risk deciles to assess calibration. Overall calibration was assessed using the Hosmer-Lemeshow approach. Calibration was also assessed visually by plotting model-based versus nonparametric estimates of 10-year cumulative incidence (Methods section in the Data Supplement). External validation was performed in MESA using the same approach, fitting the model from derivation sample with the null subdistribution hazard derived from the FHS sample. MESA was selected because the validation cohort after CHS, PREVEND, and FHS data had already been merged and was deemed a reasonable validation cohort given a comparable age and sex distribution with the other 3 cohorts.
In secondary analyses, we examined whether variables were associated differentially with risk of HFpEF versus HFrEF. We took all covariates from HFpEF and HFrEF models, then we compared subtype-specific coefficients using the Lunn-McNeil method. 22 Given Predicting Heart Failure Subtypes the lack of consensus around which LVEF cut point is used to define HF subtypes, we repeated primary analyses after reclassification of HFpEF and HFrEF cases using and LVEF of 50%. In exploratory analyses, sex*covariate interactions were tested by adding interaction terms to HF subtype-specific models. Stratified age-and sex-adjusted models by cohort and derivation/validation sets were constructed to compare effects among subgroups. All statistical analyses were conducted with SAS version 9.4 for Windows (Cary, NC).
Results
In the primary cohorts, there were 22 142 participants: 9496 (43%) from FHS, 5277 (24%) from CHS, and 7369 (33%) from PREVEND. Mean ages of participants were 58±14 years in FHS, 73±6 years in CHS, and 49±12 years in PREVEND; more than a half of participants were women. Baseline clinical characteristics by cohort are detailed in Table 1 .
Cumulative Incidence of HFpEF and HFrEF
During a mean follow-up of 13.2±3.6 years, there were 715 incident HF events in FHS, of which 636 (89%) were classified according to HF subtype. Similarly, during 11.4±4.3 years in CHS, there were 1304 HF events, of which 724 (56%) were classified. In PREVEND, there were 306 incident HF events during 11.5±2.9 years of follow-up, all of which were classified.
In total, across the 3 cohorts, there were 1666 classified HF events: 795 (48%) individuals were classified as HFpEF and 871 (52%) as HFrEF. Among classified HF, frequencies of HF subtypes varied by cohort: HFpEF was more common in CHS among classified events (53%), whereas HFrEF was more common in FHS (54%) and PREVEND (63%). Cohortspecific cumulative incidence rates of HFpEF and HFrEF are presented in the Figure.
Derivation of HFpEF and HFrEF-Specific Risk Prediction Models
Derivation and validation samples were created from pooled FHS, CHS, and PREVEND cohorts using a random 2:1 split. Baseline characteristics were similar across derivation (n=14 759) and validation (n=7383) samples ( Table I in the  Data Supplement). HF subtype-specific predictors were first evaluated in the derivation cohort in age-and sex-adjusted analyses. Significant predictors of incident HFpEF included age, systolic blood pressure, body mass index, HDL cholesterol, antihypertensive treatment, diabetes mellitus, and previous myocardial infarction (MI) when using a Bonferroni-corrected P-value threshold ( Table 2) . Predictors of incident HFrEF included age, sex, systolic and diastolic blood pressure, HDL cholesterol, body mass index, smoking status, antihypertensive treatment, ECG LV hypertrophy, left bundle branch block, diabetes mellitus, previous MI, and previous stroke in age-and sex-adjusted models ( Table 2) .
Multivariable models were then developed using a stepwise approach to predict HFpEF and HFrEF separately, with age and sex forced in. The final HFpEF-specific risk model included age, sex, systolic blood pressure, body mass index, antihypertensive treatment, and previous MI. Specifically, the relative risk of HFpEF increased 90% per 10 years of age (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.74-2.07), 14% per 20 mm Hg systolic blood pressure (HR, 1.14; 95% CI, 1.05-1.24), 28% per 4 kg/m 2 body mass index (HR, 1.28; 95% CI, 1.21-1.37), 42% if taking antihypertensive treatment (HR, 1.42; 95% CI, 1.18-1.71), and 48% with previous MI (HR, 1.48; 95% CI, 1.12-1.96; Table 3 ). Sex was forced into the model and did not predict HFpEF in multivariable analyses (P=0.43).
The HFrEF-specific multivariable risk model included age, sex, systolic blood pressure, body mass index, smoking status, antihypertensive treatment, LV hypertrophy, left bundle branch block, diabetes mellitus, and previous MI. Specifically, the relative risk of HFrEF increased 66% per 10 years of age (HR, 1.66; 95% CI, 1.52-1.80), 84% for men ( 
Performance Metrics and Validation of HF Subtype-Specific Risk Models
The final HFpEF risk prediction model had a c-statistic of 0.80 (95% CI, 0.78-0.82) in the derivation sample. When the HFpEF model was applied to the validation sample, the c-statistic was 0.79 (95% CI, 0.77-0.82). The model was well calibrated in both derivation and validation sets (χ 2 statistic 5.29; P=0.73 and χ 2 statistic 9.02; P=0.34, respectively).
The c-statistic for the HFrEF-specific prediction model was 0.82 (95% CI, 0.80-0.84) in the derivation sample. In the validation sample, the c-statistic was 0.80 (95% CI, 0.78-0.83). Calibration was reasonable in derivation and validation sets (χ 2 statistic 13.35, P=0.10 and χ 2 statistic 14.19, P=0.08, respectively).
External Validation of HF Subtype-Specific Risk Models
External validation was performed among 6678 MESA participants, with a mean age of 62±10 years and 53% women ( Table 1) . During a mean follow-up of 10.4±2.6 years, there were 254 incident HF events, of which 114 were classified as HFpEF and 111 as HFrEF. The HFpEF-specific model had good discrimination with a c-statistic of 0.76 (95% CI, 0.71-0.80), as did the HFrEF-specific model (c-statistic 0.76; 95% CI, 0.71-0.80). Both models had good calibration in MESA (χ 2 statistic 4.54; P=0.81 for HFpEF and χ 2 statistic 7.56; P=0.48 for HFrEF).
Differential Effects of Predictors on HFpEF Versus HFrEF
We tested whether clinical covariates had identical effects on HFpEF versus HFrEF (pooled FHS, CHS, and PREVEND Predicting Heart Failure Subtypes participants) using the Lunn-McNeil method ( Table 4 ). 22 Men had higher risk than women for HFrEF but not for HFpEF (P for comparison <0.0001). Left bundle branch block and previous MI increased risk more strongly for HFrEF than for HFpEF (P for comparison ≤0.0008 for both). Additionally, age seemed to have a greater risk associated with HFpEF than HFrEF; smoking status and LV hypertrophy were more strongly associated with HFrEF than HFpEF (P for comparison ≤0.02 for all).
Secondary Analyses and Interactions
After reclassifying HF subtypes using an LVEF 50% as the cut point, we found that among a total of 1891 classified HF events across the 4 cohorts, 105 of 909 individuals originally deemed HFpEF were reclassified as HFrEF (5.6% of all classified HF). Age-and sex-adjusted analyses demonstrated minor differences, and the final risk prediction models were also similar after reclassification, with similar directionality and magnitude of effects and slightly less significant P values (28) Asian, n (%)
Chinese American, n (%) 0 (0) 0 (0) 0 (0) 798 (12) Hispanics, n (%) 0 (0) 0 (0) 0 (0) 1481 (22) Other, n (%) 15 In exploratory analyses, we found no significant sex*covariate interactions in the final HF subtype-specific models using the derivation cohort (Table VI in the Data Supplement). We also examined age-and sex-adjusted HRs of all predictors in relation to HF subtypes in the following subgroups: derivation and validation samples and 3 primary cohorts. Results were similar across subgroups (Tables VII and VIII 
Discussion
We developed and validated separate risk prediction models for HFpEF and HFrEF among 4 longitudinal community-based cohorts with >1800 incident HF events classified by subtype. These models accounted for multiple competing risks, including death and other HF subtype. Specifically, age, blood pressure, body mass index, and previous MI predicted HFpEF, whereas these risk factors in addition to sex, smoking status, LV hypertrophy, left bundle branch block, and diabetes mellitus predicted incident HFrEF. HF subtype-specific risk models seemed robust on internal and external validation.
Given the substantial morbidity, mortality, and rising costs associated with HF, 2,23 preventive strategies are urgently needed. 6 Fundamental elements for developing a disease prevention strategy are a clear understanding of disease risk factors, and the ability to define an at-risk population. Previous studies have focused on HF risk prediction models among community-based samples, [24] [25] [26] [27] [28] [29] [30] individuals captured at the insurance interface, 31 and specific populations enrolled in clinical trials. 32, 33 Across most studies including ours, age, male sex, hypertension, obesity, diabetes mellitus, and previous MI are predictors of risk for incident HF, as summarized in a recent systematic review. 7 However, the clinical applicability of existing HF risk prediction models remains unclear, as generalizability has not been tested rigorously. One strength of our study is both internal and external validation of our risk prediction models with robust discrimination and calibration in >25 000 individuals. We chose LVEF 45% as the cutoff to define HF subtypes, consistent with previously published articles. 34 In addition, Solomon et al 35 previously demonstrated that the lower the LVEF, the higher the risk of adverse events. 35 However, once elevated to >45%, LVEF no longer contributes to cardiovascular risk. In addition, our secondary analyses after reclassification of HF subtypes using a cutoff of LVEF 50% demonstrated similar results.
Importantly, no previous HF risk prediction studies examined HF subtype-specific prediction models. Although the clinical phenotype of HF is largely similar, previous evidence suggests that HFpEF and HFrEF might be separate entities within the spectrum of HF, with distinct causes as evidenced by unique patterns of cardiac and cellular remodeling and responses to therapy. 9, 36 We hypothesized that HF risk prediction may similarly be distinct when examining HFpEF versus HFrEF. Indeed, previous studies have indicated different clusters of risk factors preceding HFpEF versus HFrEF. [10] [11] [12] However, given the challenge of small sample sizes and multiple competing risks, risk prediction was not previously reported separately for these HF subtypes. We now extend these findings across 4 richly phenotyped community-based cohorts and have developed and validated HF subtype-specific risk prediction models using readily available clinical measures. Although both models had excellent discrimination, the HFrEF model had a higher c-statistic when compared with the HFpEF model in both the derivation and internal validation samples.
Our findings show substantial overlap in modifiable and nonmodifiable risk factors leading to both subtypes of HF (age, obesity, hypertension, previous MI) but also support some differences in predictors of HFpEF versus HFrEF. Specifically, male sex, ECG LV hypertrophy, left bundle branch block, previous MI, and smoking status were more strongly associated with HFrEF compared with HFpEF, and age was a stronger predictor 
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of HFpEF compared with HFrEF. These differences were also reflected in the stepwise selection process of unique covariates included in the final HF subtype-specific models, and they have been substantiated by previous studies. For example, although ischemic heart disease can lead to both HFpEF and HFrEF, previous MI was more frequently associated with HFrEF in the ADHERE registry, 37 and thus, it is not surprising that risk factors for coronary artery disease (previous MI, male sex, smoking) are more strongly associated with HFrEF in our study. Similarly, left bundle branch block is known to lead to deterioration of LV systolic function and incite progression to HF via electrical and mechanical remodeling 38 and supports our observed association with HFrEF. The finding that ECG LV hypertrophy is more strongly associated with HFrEF versus HFpEF is notable. LV hypertrophy can progress to both HFpEF and HFrEF in hypertensive heart disease. 39 Differential effects of LV hypertrophy on HFpEF and HFrEF may be because of poor sensitivity of ECG LV hypertrophy for detecting LV hypertrophy on echo, particularly in women and in the setting of obesity. 40 Although we found that discrimination of the HFpEF risk prediction model was not as good as that of the HFrEF prediction model, our data provide novel insight into this phenotype as well. For instance, although it has been recognized that many patients with HFpEF have coronary artery disease, this is generally not viewed as a predictor for HFpEF. Herein, we demonstrate that a history of MI is predictive for the development of HFpEF, although less strong than it is for HFrEF. Likewise, it has been postulated that HFpEF is a disease of elderly women, but the value of sex for prediction of HFpEF was not as strong as been put forward before. Clearly, HFpEF risk prediction remains more difficult, and additional parameters may improve our models.
Several limitations deserve mention. First, our models focused only on readily available clinical characteristics, similar to 10-year cardiovascular disease risk prediction models. 41 We acknowledge that the use of a Bonferroni-corrected P value threshold is a conservative approach and may result in exclusion of predictors with small or modest effects from the final risk prediction models. Previous studies have demonstrated the potential utility of imaging and biomarkers, including natriuretic peptides and high-sensitivity troponin, in refining clinical HF risk prediction models. 29, [42] [43] [44] [45] Whether the addition of biomarkers and other noncardiac comorbidities, such as pulmonary disease, anemia, sleep apnea, and kidney disease, may improve discrimination and differentially predict HF subtype will need to be examined in future studies. Next, HFpEF and HFrEF by definition included only individuals who underwent LV function assessment at or around the time of HF presentation, leaving 27% of cases as unclassified HF. This may have led to differential bias and potential cohort-based differences given that a greater proportion of HF cases in CHS were unclassified. However, most covariates had similar effects across cohorts, and given widely varying proportions of unclassified HF among cohorts, this may be reassuring that unclassified HF may not have differentially affected HF subtypes. Definitions of HF and LV hypertrophy *Hazard ratio is expressed per increase in continuous variables as specified in the table, and for presence vs absence of dichotomous variables. To convert cholesterol to mmol/L, multiply values by 0.0259. Predicting Heart Failure Subtypes varied slightly by cohort and may underlie cohort-specific differences observed. We did not account for relatedness among Framingham original cohort and offspring samples, which may have influenced FHS-specific results. External validation in the ethnically diverse MESA cohort demonstrated robust risk models, although we did not have adequate power to perform race-specific HF subtype analyses.
In summary, we developed and validated separate risk prediction models for HFpEF and HFrEF by leveraging data from 4 longitudinal community-based cohorts spanning a broad range of ages. We found substantial overlap in risk factors for incident HFpEF and HFrEF, although some risk factors displayed differential effects on HF subtypes. While therapies to prevent mortality in patients with symptomatic HF are predicated on the distinction between HFpEF and HFrEF, 4 current preventive strategies in the preclinical stages of HF do not distinguish between HF subtype. Recent data support the notion that a screening strategy targeting at-risk patients in primary care clinics may prevent HF-related outcomes, 46 yet community-wide screening using biomarkers or echocardiography is not supported. 47 Further studies are needed to examine the clinical utility of HF subtype risk prediction, with the ultimate goal of targeted preventive strategies. Bold face indicates significant P value using a Bonferroni-corrected threshold of 0.005 for number of variables tested. BP indicates blood pressure; CI, confidence interval; HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; and sHR, subdistribution hazard ratio.
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CLInICAL PERSPECTIVE
Heart failure (HF) accounts for a substantial burden of total healthcare costs worldwide, and about half of individuals presenting with HF have heart failure with preserved as opposed to reduced ejection fraction (HF with preserved ejection fraction and HF with reduced ejection fraction, respectively). Risk prediction specific to HF subtype may be able to improve upon existing risk prediction algorithms that have been developed for overall HF and to guide future preventive strategies. We developed and validated separate risk prediction models for HF with preserved ejection fraction and HF with reduced ejection fraction by leveraging data from 4 longitudinal community-based cohorts spanning a broad range of ages. We found substantial overlap in risk factors for incident HF with preserved ejection fraction and HF with reduced ejection fraction, although some risk factors displayed differential effects on HF subtypes. Recent data support the notion that a screening strategy targeting at-risk patients in primary care clinics may prevent HF-related outcomes. Future studies are needed to examine the clinical utility of HF subtype-specific risk prediction, with the ultimate goal of targeted preventive strategies.
